Inclusion Criteria:

- Patients with histologically proven cervical carcinoma (All histological subtype will
be included).

- Patients who have stage IVB, recurrent or persistent disease.

- Patients who are not amenable to curative treatment with surgery and/or radiotherapy.

- Patients who have not received chemotherapy or chemoradiotherapy after diagnosis of
recurrent, persistent, or stage IVB disease.

- If the patient have received chemotherapy, radiotherapy or chemoradiotherapy as
previous treatment, following interval must have elapsed from the last administration
of treatment:

1. Chemotherapy: 21 days

2. Radiotherapy: 21 days*

3. Chemoradiotherapy: 42 days*

If there have been residual disease in previously irradiated field and without disease
progression since the (chemo) radiotherapy, 90 days must have elapsed after the last
administration of irradiation.

- Patients who have adequate hematologic, hepatic and renal functions as defined below:

- Hemoglobin: ≥ 8.0 g/dL

- Neutrophil count: ≥ 2,000/mm^3

- Platelet count: ≥ 100,000/mm^3

- Total serum bilirubin: ≤ 1.5 times the upper limits of normal (ULN)

- AST (GOT), ALT (GPT): ≤ 2.5 times the ULN. If abnormal values are associated
with hepatic metastasis: ≤ 5.0 times the ULN

- Serum creatinine: ≤ ULN or creatinine clearance: ≥ 50 ml/min

- Patients who have an ECOG performance status : 0-1.

- Age: ≥ 20 years old.

- Patients who can take pills orally.

- Patients who signed the written consent form.

Exclusion Criteria:

- Patients who have known hypersensitivity to 5-FU or Cisplatin.

- Patients who are receiving concomitant treatment with drugs interacting with S-1.

- Patients who are receiving concomitant treatment with drugs interacting with
Cisplatin.

- Patients who were administered other investigational products within 30 days before
the initiation of study treatment.

- Patients who were previously treated with S-1.

- Patients who had received platinum-containing chemotherapy or chemoradiotherapy and
whose disease progressed during the therapy.

- Patients who suffer from active infection (e.g. fever ≥ 38°C).

- Patients who have serious complications.

- Patients with bleeding which requires hemostasis treatment.

- Patients with bilateral hydronephrosis which cannot be alleviated by ureteral stents
or percutaneous drainage.

- Patients with uncontrolled pleural effusion and/or ascites requiring drainage at
least twice a week.

- Patients with symptomatic brain metastasis or history of brain metastasis.

- Patients who have unmanageable bowel movement (ex. Watery stool, chronic
constipation).

- Patients with active double cancer.

- Patients who are pregnant or lactating.

- Patients who are considered to be inappropriate to the subject of this study by the
investigator.